6CM
ANRO icon

683 Capital Management’s Alto Neuroscience ANRO Stock Holding History

683 Capital Management’s Portfolio ANRO Stock Details ANRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$899K Sell
40,000
-24,782
-38% -$459K 0.05% 142
2025
Q4 		$1.15M Buy
+64,782
New +$816K 0.05% 128

Other funds holding ANRO

AWG
Alpha Wave Global New York $791M AUM 113.77% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
SSC
Spruce Street Capital New York $416M AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

683 Capital Management's ANRO Position: Q1 2026 in Review

683 Capital Management reduced its Alto Neuroscience (ANRO) stake by 38% in Q1 2026, selling an estimated $459K and leaving 40,000 shares worth $899K. The position accounts for 0.05% of the portfolio, ranked #142.

683 Capital Management first reported a position in ANRO in Q4 2025 and has held it in 2 quarters since. The position peaked at $1.15M in Q4 2025. 110 funds tracked by Wall St. Rank hold ANRO as of Q1 2026.

  • 683 Capital Management held 40,000 shares of Alto Neuroscience worth $899K as of Q1 2026.
  • 683 Capital Management sold 24,782 Alto Neuroscience shares in Q1 2026, an estimated $459K.
  • Alto Neuroscience made up 0.05% of 683 Capital Management's portfolio in Q1 2026, its #142 holding.
  • 683 Capital Management first reported a position in Alto Neuroscience in Q4 2025 and has held it in 2 quarters since.
  • 683 Capital Management's Alto Neuroscience position peaked at $1.15M in Q4 2025.
  • 110 funds tracked by Wall St. Rank held Alto Neuroscience as of Q1 2026.

Based on 683 Capital Management's 13F filing for Q1 2026, filed 15 May 2026.